Now that Regulus Therapeutics Inc’s volume has hit 0.83 million, investors get a glimpse of its size.

Regulus Therapeutics Inc (NASDAQ: RGLS) on Tuesday, plunged -2.86% from the previous trading day, before settling in for the closing price of $2.80. Within the past 52 weeks, RGLS’s price has moved between $0.82 and $3.79.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


A company in the Healthcare sector has jumped its sales by 1867.07% annually for the last half of the decade. The company achieved an average annual earnings per share of 67.88%. With a float of $57.42 million, this company’s outstanding shares have now reached $65.47 million.

In an organization with 30 employees, it is important to assess its efficiency.

Regulus Therapeutics Inc (RGLS) Insider Updates

Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Regulus Therapeutics Inc is 12.29%, while institutional ownership is 23.55%. The most recent insider transaction that took place on Jan 18 ’24, was worth 17,359. In this transaction Chief Executive Officer of this company sold 14,580 shares at a rate of $1.19, taking the stock ownership to the 57,112 shares. Before that another transaction happened on Jan 18 ’24, when Company’s Chief Financial Officer sold 5,468 for $1.19, making the entire transaction worth $6,510. This insider now owns 5,782 shares in total.

Regulus Therapeutics Inc (RGLS) Performance Highlights and Predictions

As on 12/30/2023, Multinational firm has announced its last quarter scores, in which it reported -$0.4 earnings per share (EPS) for the period falling under the consensus outlook (set at -$0.39) by -$0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 67.88% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 39.60% during the next five years compared to 50.96% growth over the previous five years of trading.

Regulus Therapeutics Inc (NASDAQ: RGLS) Trading Performance Indicators

Regulus Therapeutics Inc (RGLS) is currently performing well based on its current performance indicators. A quick ratio of 2.96 was reported for the most recent quarter.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.59, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.61 in one year’s time.

Technical Analysis of Regulus Therapeutics Inc (RGLS)

Let’s dig in a bit further. During the last 5-days, its volume was 0.85 million. That was inferior than the volume of 3.01 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 76.55%. Additionally, its Average True Range was 0.31.

During the past 100 days, Regulus Therapeutics Inc’s (RGLS) raw stochastic average was set at 60.52%, which indicates a significant decrease from 74.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 97.26% in the past 14 days, which was lower than the 107.10% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $1.77, while its 200-day Moving Average is $1.48. However, in the short run, Regulus Therapeutics Inc’s stock first resistance to watch stands at $2.85. Second resistance stands at $2.97. The third major resistance level sits at $3.14. If the price goes on to break the first support level at $2.56, it is likely to go to the next support level at $2.39. Assuming the price breaks the second support level, the third support level stands at $2.27.

Regulus Therapeutics Inc (NASDAQ: RGLS) Key Stats

Market capitalization of the company is 178.08 million based on 65,465K outstanding shares. Right now, sales total 0 K and income totals -30,040 K. The company made 0 K in profit during its latest quarter, and -8,060 K in sales during its previous quarter.